Effects of Pitavastatin on Monocyte, Endothelial Dysfunction and HDL-C in Subjects With Metabolic Syndrome

Inclusion Criteria: * Patients with metabolic syndrome * Patients with LDL-C \> 130mg/dL * Eligible, able to participate and have given informed consent Exclusion Criteria: * Body Mass Index \>35 kg/m2 * LDL-C \> 190mg/dL * Fasting triglycerides \> 400 mg/dL * Diabetes mellitus (fasting glucose \>7 mmol/L) or taking diabetic therapy * Uncontrolled hypertension (Systolic Blood Pressure \>= 140 mmHg or Diastolic Blood Pressure \>= 90mmHg) * Any conditions that cause secondary dyslipidaemia or increase the risk of statin therapy * ALAT and ASAT \>3 x ULRR * Impaired renal function (Serum Creatinine \>1.5 x ULRR or eGFR \<60 mL/min) * History of any muscle disease or unexplained elevation (\>3 x ULRR) of serum creatine kinase * Evidence of symptomatic heart failure (NYHA class III or IV) * Current or recent user of supplements or medications known to alter lipid metabolism